UPDATE -- OncoCyte To Report Third Quarter Financial Results On November 10, 2016

ALAMEDA, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it will release its financial and operating results for the quarter ended September 30, 2016 on Thursday, November 10, 2016 after the close of the U.S. financial markets. The Company will host a conference call on Thursday, November 10, 2016 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results along with recent corporate developments.

The dial-in number in the U.S./Canada is 877-524-8416, for international participants the number is 412-902-1028. For all callers, refer to Conference ID 13649349. To access the live webcast, go to the investor relations section on the company's website,  http://investors.oncocyte.com/events-and-presentations.

A replay of the conference call will be available for seven business days beginning about two hours after the conclusion of the live call, by calling 877-660-6853 toll-free (from U.S./Canada); international callers dial 201-612-7415. Use the Conference ID 13649349. Additionally, the archived webcast will be available  http://investors.oncocyte.com/events-and-presentations.

About OncoCyte CorporationOncoCyte is primarily focused on the development and commercialization of novel, non-invasive blood and urine ("liquid biopsy") diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients. While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte's pipeline products are intended to be confirmatory diagnostics for detecting lung, bladder and breast cancer. OncoCyte's diagnostic tests are being developed using proprietary sets of genetic and protein markers that differentially express in specific types of cancer.

If you liked this article you might like

10 Worst-Performing Small-Cap Stocks in 2016

Allison Transmission’s CEO Says Some Weak Markets Have Bottomed

The Deal: Nielsen Pockets $950 Million to Finance Arbitron Acquisition

Citi Considers Partial Sale of OneMain: Report

Citi Considers Partial Sale of OneMain: Report